Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present GeoVax Labs, Inc. (OTC: GOVX).

Full DD Report for GOVX

You must become a subscriber to view this report.


Recent News from (OTC: GOVX)

GeoVax Strengthens Scientific Staff and Expertise
ATLANTA, GA, Aug. 29, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE --  GeoVax Labs, Inc . (OTCQB: GOVX), a biotechnology company developing human vaccines, today announced the strengthening of its scientific team through the addition of two PhD-level scientists.   Mary Hauser, P...
Source: GlobeNewswire
Date: August, 29 2018 09:00
GeoVax Comments on Recent Paper Addressing Safety Concerns Over Ebola Vaccines Under Development
Design of GeoVax Ebola Vaccine Expected to Overcome Potential Safety Issues ATLANTA, GA, Aug. 23, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc . (OTCQB: GOVX), a biotechnology company developing human vaccines, today commented on a paper published by Iampietro et al, f...
Source: GlobeNewswire
Date: August, 23 2018 09:00
GeoVax and PharmaJet to Collaborate On Development of Needle-Free Vaccine for Zika Virus
GeoVax Zika Virus Vaccine Provided 100% Protection in Animal Challenge Model ATLANTA, GA, Aug. 21, 2018 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc . (OTCQB: GOVX), a biotechnology company developing human vaccines, announced today that it is collaborating with   PharmaJet, Inc ., ...
Source: GlobeNewswire
Date: August, 21 2018 09:00
GeoVax Announces Appointment of David Dodd as Chairman, President and Chief Executive Officer
Current President & CEO Robert McNally to Retire Effective August 31 ATLANTA, GA, Aug. 14, 2018 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc . (OTCQB: GOVX), a biotechnology company developing human vaccines, announced today that David A. Dodd has been appointed President and Chief Execu...
Source: GlobeNewswire
Date: August, 14 2018 09:00
GeoVax Reports 2018 Second Quarter Financial Results and Provides Corporate Update
ATLANTA, Aug. 07, 2018 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines using its novel viral vector platform technology, announced its financial results for the quarter ended June 30, 2018, and provided an overview of recent accomplishm...
Source: GlobeNewswire
Date: August, 07 2018 13:00
GeoVax and Emory University to Collaborate on HPV Therapeutic Program for Head and Neck Cancers
GeoVax Continues Expansion of its MVA-VLP Vaccine Pipeline   with Multiple Collaborations in Infectious Disease and Immuno-oncology ATLANTA, GA, July 30, 2018 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc . (OTCQB: GOVX), a biotechnology company developing human vaccines, announced toda...
Source: GlobeNewswire
Date: July, 30 2018 09:00
GeoVax to Present at the American Society for Virology 2018 Annual Meeting
ATLANTA, GA, July 09, 2018 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (OTCQB: GOVX), winner of the 2018 “Best Biotech” at the Vaccine Industry Excellence (ViE) Awards during the World Vaccine Congress, announced today that its Chief Scientific Officer, Dr. Farshad Guirakhoo, will d...
Source: GlobeNewswire
Date: July, 09 2018 09:00
GeoVax to Present at the 2018 ASM Microbe Conference
ATLANTA, GA. , May 30, 2018 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (OTCQB: GOVX), winner of the 2018 “Best Biotech” Vaccine Industry Excellence Award at the World Vaccine Congress, announced today that it will be presenting its latest data in a late-breaking poster presentation...
Source: GlobeNewswire
Date: May, 30 2018 09:00
GeoVax Awarded NIH Grant for Novel Zika Vaccine
ATLANTA, GA, , May 24, 2018 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc . (OTCQB: GOVX), a biotechnology company developing human vaccines, announced today that the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has awarded the Co...
Source: GlobeNewswire
Date: May, 24 2018 09:00
GeoVax to Conduct Partnering Meetings During BIO International Convention June 4-7
CEO Robert McNally to Speak as part of BIO’s One Health Day Program ATLANTA, GA., May 22, 2018 (GLOBE NEWSWIRE) --   GeoVax Labs, Inc . (OTCQB: GOVX), a biotechnology company developing human vaccines and winner of the 2018 “Best Biotech” Vaccine Indu...
Source: GlobeNewswire
Date: May, 22 2018 09:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-140.0270.0270.02760.0262,411,693
2018-12-130.02650.02650.027350.0231165,443
2018-12-120.0270.02750.0290.027505,924
2018-12-110.027750.0280.0290.02775254,167
2018-12-100.0260.0280.0280.026207,519

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-141,504,3922,411,69362.3791Short
2018-12-1318,913165,44311.4317Cover
2018-12-12273,200505,92454.0002Short
2018-12-11100,800254,16739.6590Short
2018-12-1071,900207,51934.6474Cover

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on GOVX.


About GeoVax Labs, Inc. (OTC: GOVX)

Logo for GeoVax Labs, Inc. (OTC: GOVX)

GeoVax Labs, Inc. is a clinical stage biotechnology company developing human vaccines against infectious diseases using our Modified Vaccinia Ankara Virus Like Particle MVA VLP vaccine platform. Our current development programs are focused on preventive vaccines against HIV, Zika virus, Hemorrhagic Fever viruses Ebola, Sudan, Marburg, Lassa , and malaria, as well as therapeutic vaccines for chronic Hepatitis B infections and cancers. Our vaccine platform supports in vivo production of non infectious VLPs in the person receiving the vaccine. The production of VLPs in the person being vaccinated mimics virus production in a natural infection, stimulating both the humoral and cellular arms of the ijmmune system to recognize, prevent, and control the target infection.

 

Contact Information

 

 

Current Management

  • David Dodd / Outside Director
  • Robert T. McNally / CEO, President
  • Mark W. Reynolds / CFO, Corporate Secretary
  • Farshad Guirakhoo / Chief Scientific Officer
  • Harriet L. Robinson / Director, R amp D
  • John N. Spencer, Jr. / Outside Director
  • Dean G. Kollintzas / Outside Director
  • Randal D. Chase / Outside Director
  • David Dodd / Chairman
  • Robert T. McNally /
  • Harriet L. Robinson /

Current Share Structure

  • Market Cap: $4,162,736 - 03/09/2018
  • Authorized: 600,000,000 - 12/31/2017
  • Issue and Outstanding: 106,736,810 - 12/31/2017
  • Float: 105,225,604 - 12/31/2017

 


Recent Filings from (OTC: GOVX)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 03 2018
Prospectus filed under Rule 424(b)(3)
Filing Type: 424B3Filing Source: edgar
Filing Date: May, 03 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 03 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 27 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 27 2018
Prospectus filed under Rule 424(b)(1)
Filing Type: 424B1Filing Source: edgar
Filing Date: April, 03 2018
Amendment to a SC 13D filing
Filing Type: SC 13D/AFiling Source: edgar
Filing Date: March, 29 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 23 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 23 2018
Post-effective amendment to an S-Type filing
Filing Type: POS AMFiling Source: edgar
Filing Date: March, 23 2018

 

 


Daily Technical Chart for (OTC: GOVX)

Daily Technical Chart for (OTC: GOVX)


Stay tuned for daily updates and more on (OTC: GOVX)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: GOVX)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in GOVX is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of GOVX and does not buy, sell, or trade any shares of GOVX. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/